Free Trial
NASDAQ:ADPT

Adaptive Biotechnologies (ADPT) Stock Price, News & Analysis

$3.59
-0.02 (-0.55%)
(As of 05/20/2024 ET)
Today's Range
$3.49
$3.63
50-Day Range
$2.34
$3.96
52-Week Range
$2.28
$9.08
Volume
961,640 shs
Average Volume
1.61 million shs
Market Capitalization
$529.06 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.80

Adaptive Biotechnologies MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
89.4% Upside
$6.80 Price Target
Short Interest
Bearish
8.17% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.79
Upright™ Environmental Score
News Sentiment
0.78mentions of Adaptive Biotechnologies in the last 14 days
Based on 3 Articles This Week
Insider Trading
Selling Shares
$428,090 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.30) to ($1.08) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.74 out of 5 stars

Medical Sector

187th out of 917 stocks

Biological Products, Except Diagnostic Industry

22nd out of 149 stocks

ADPT stock logo

About Adaptive Biotechnologies Stock (NASDAQ:ADPT)

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.

ADPT Stock Price History

ADPT Stock News Headlines

Adaptive Biotechnologies Corporation (ADPT)
Adaptive Biotechnologies: Q1 Earnings Snapshot
Adaptive Biotechnologies Q1 Loss decreases, beats estimates
See More Headlines
Receive ADPT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Adaptive Biotechnologies and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
5/07/2024
Today
5/21/2024
Next Earnings (Estimated)
8/07/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:ADPT
Employees
709
Year Founded
2009

Price Target and Rating

Average Stock Price Target
$6.80
High Stock Price Target
$10.00
Low Stock Price Target
$5.00
Potential Upside/Downside
+89.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
6 Analysts

Profitability

Net Income
$-225,250,000.00
Net Margins
-123.24%
Pretax Margin
-123.29%

Debt

Sales & Book Value

Annual Sales
$170.28 million
Book Value
$2.13 per share

Miscellaneous

Free Float
138,231,000
Market Cap
$529.06 million
Optionable
Optionable
Beta
1.27

Social Links

10 Best Stocks to Own in 2024 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

ADPT Stock Analysis - Frequently Asked Questions

Should I buy or sell Adaptive Biotechnologies stock right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Adaptive Biotechnologies in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" ADPT shares.
View ADPT analyst ratings
or view top-rated stocks.

What is Adaptive Biotechnologies' stock price target for 2024?

6 brokers have issued twelve-month price objectives for Adaptive Biotechnologies' stock. Their ADPT share price targets range from $5.00 to $10.00. On average, they anticipate the company's share price to reach $6.80 in the next twelve months. This suggests a possible upside of 89.4% from the stock's current price.
View analysts price targets for ADPT
or view top-rated stocks among Wall Street analysts.

How have ADPT shares performed in 2024?

Adaptive Biotechnologies' stock was trading at $4.90 at the beginning of 2024. Since then, ADPT shares have decreased by 26.7% and is now trading at $3.59.
View the best growth stocks for 2024 here
.

When is Adaptive Biotechnologies' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 7th 2024.
View our ADPT earnings forecast
.

How were Adaptive Biotechnologies' earnings last quarter?

Adaptive Biotechnologies Co. (NASDAQ:ADPT) issued its quarterly earnings results on Tuesday, May, 7th. The company reported ($0.33) EPS for the quarter, topping analysts' consensus estimates of ($0.35) by $0.02. The business earned $41.87 million during the quarter, compared to analyst estimates of $38.78 million. Adaptive Biotechnologies had a negative net margin of 123.24% and a negative trailing twelve-month return on equity of 56.58%. The business's quarterly revenue was up 11.2% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.40) earnings per share.

What ETFs hold Adaptive Biotechnologies' stock?

ETFs with the largest weight of Adaptive Biotechnologies (NASDAQ:ADPT) stock in their portfolio include ARK Genomic Revolution ETF (ARKG) and Amplify Treatments, Testing and Advancements ETF (GERM).First Trust Nasdaq Lux Digital Health Solutions ETF (EKG).

What guidance has Adaptive Biotechnologies issued on next quarter's earnings?

Adaptive Biotechnologies updated its first quarter 2024 earnings guidance on Tuesday, April, 2nd. The company provided EPS guidance of for the period. The company issued revenue guidance of $41.0 million-$43.0 million, compared to the consensus revenue estimate of $38.2 million.

What is Chad Robins' approval rating as Adaptive Biotechnologies' CEO?

51 employees have rated Adaptive Biotechnologies Chief Executive Officer Chad Robins on Glassdoor.com. Chad Robins has an approval rating of 92% among the company's employees. This puts Chad Robins in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Adaptive Biotechnologies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Adaptive Biotechnologies investors own include NVIDIA (NVDA), Alibaba Group (BABA), QUALCOMM (QCOM), Johnson & Johnson (JNJ), Advanced Micro Devices (AMD), CrowdStrike (CRWD), Home Depot (HD), Inovio Pharmaceuticals (INO), PayPal (PYPL) and Tesla (TSLA).

When did Adaptive Biotechnologies IPO?

Adaptive Biotechnologies (ADPT) raised $200 million in an initial public offering on Thursday, June 27th 2019. The company issued 12,500,000 shares at $15.00-$17.00 per share. Goldman Sachs, J.P. Morgan and BofA Merrill Lynch served as the underwriters for the IPO and Cowen, Guggenheim Securities, William Blair and BTIG were co-managers.

Who are Adaptive Biotechnologies' major shareholders?

Adaptive Biotechnologies' stock is owned by many different retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (8.73%), Sumitomo Mitsui Trust Holdings Inc. (4.26%), Nikko Asset Management Americas Inc. (4.19%), Nordea Investment Management AB (0.58%), Essex Investment Management Co. LLC (0.19%) and Lazard Asset Management LLC (0.12%). Insiders that own company stock include Chad M Cohen, Chad M Cohen, Chad M Robins, Chad M Robins, Egon Durban, Euclidean Capital Llc, Harlan S Robins, Harlan S Robins, Julie Rubinstein, Jyoti Palaniappan, Kyle Piskel, Lance Baldo, Michelle Renee Griffin, Nitin Sood, R Mark Adams, Stacy L Taylor and Tycho Peterson.
View institutional ownership trends
.

How do I buy shares of Adaptive Biotechnologies?

Shares of ADPT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ADPT) was last updated on 5/21/2024 by MarketBeat.com Staff

From Our Partners